Even though the annual incidence rate of measles has dramatically decreased in industrialised countries since the implementation of universal immunisation programmes, cases continue to occur in countries where endemic measles transmission has been interrupted and in countries where adequate levels of immunisation coverage have not been maintained. The objective of this study is to develop a model to estimate the average cost per measles case and per adverse event following measles immunisation using the Netherlands (NL), the United Kingdom (UK) and Canada as examples.
Parameter estimates were based on a review of the published literature. A decision tree was built to represent the complications associated with measles cases and adverse events following immunisation. Monte-Carlo Simulation techniques were used to account for uncertainty.
From the perspective of society, we estimated the average cost per measles case to be US$276, US$307 and US$254 for the NL, the UK and Canada, respectively, and the average cost of adverse events following immunisation per vaccinee to be US$1.43, US$1.93 and US$1.51 for the NL, UK and Canada, respectively.
These average cost estimates could be combined with incidence estimates and costs of immunisation programmes to provide estimates of the cost of measles to industrialised countries. Such estimates could be used as a basis to estimate the potential economic gains of global measles eradication.
Notes
Cites: Dev Biol Stand. 1979;43:273-7118067
Cites: Scand J Soc Med. 1978;6(3):111-5103198
Cites: Int J Epidemiol. 1985 Mar;14(1):153-683988430
Cites: Am J Public Health. 1985 Jul;75(7):739-443923849
Cites: Pediatrics. 1985 Oct;76(4):524-323931045
Cites: Vaccine. 1987 Jun;5(2):123-73111114
Cites: Br Med J (Clin Res Ed). 1987 Jun 13;294(6586):1527-83111623
Cites: Pediatrie. 1988;43(5):451-43200658
Cites: Int J Epidemiol. 1989 Sep;18(3):684-92807674
Cites: Vaccine. 1991 May;9(5):297-91872012
Cites: Pediatrics. 1991 Nov;88(5):881-51945626
Cites: Stat Med. 1991 Nov;10(11):1733-441792467
Cites: Int J Epidemiol. 1992 Oct;21(5):998-10061468866
Cites: Pediatr Infect Dis J. 1993 Jan;12(1):42-88417425
Cites: Dev Med Child Neurol Suppl. 1993 Jul;68:1-1188319837
Cites: Am J Public Health. 1993 Jul;83(7):1011-58328595
Cites: West J Med. 1993 Oct;159(4):455-648273330
Cites: BMJ. 1995 Jun 24;310(6995):1629-327795447
Cites: Epilepsy Res. 1995 May;21(1):43-97641675
Cites: Can Commun Dis Rep. 1995 Jul 15;21(13):117-287663460
Cites: Am J Public Health. 1995 Dec;85(12):1706-97503351
Cites: Pediatr Infect Dis J. 1996 Jan;15(1):44-88684875
Cites: West J Med. 1996 Jul-Aug;165(1-2):20-58855680
Cites: Lancet. 1997 Mar 8;349(9053):730-19078224
Cites: Am J Epidemiol. 1997 Jun 15;145(12):1127-379199543
Cites: N Z Med J. 1997 Jul 25;110(1048):270-29269289
Cites: Pediatrics. 1997 Nov;100(5):767-719346975
Cites: Aust N Z J Public Health. 1998 Feb;22(1):126-329599864